Results 231 to 240 of about 53,072 (310)

Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19

British Journal of Clinical Pharmacology, EarlyView.
Aims The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans.
Akosua A. Agyeman, Laura Buggiotti, Li‐An K. Brown, Jose A. Guerra‐Assuncao, Japhette E. Kembou‐Ringert, Wen Y. Mak, Judith Breuer, David M. Lowe, Joseph F. Standing, FLARE Investigators   +9 more
wiley   +1 more source

Algorithm-Optimized H5 Influenza mRNA Vaccine Induces Broad Immune Responses. [PDF]

Int J Mol Sci
Wang L, Peng Z, He C, Zhang J, Yu P, Huang W, Wang Y, Zhao C.   +7 more
europepmc   +1 more source

Practice, knowledge and attitude of physicians and pharmacists towards the spontaneous reporting system of adverse drug reactions in Switzerland

British Journal of Clinical Pharmacology, EarlyView.
Introduction Introduction Reporting adverse drug reactions (ADRs) is essential for detecting drug risks. Despite legal obligations in Switzerland, underreporting remains an issue. This study assessed practice, knowledge and attitudes towards the spontaneous ADR reporting system among physicians and pharmacists.
Fiona A. Strobel, Thomas Stammschulte, Patrick E. Beeler   +2 more
wiley   +1 more source

Cytomegalovirus in HIV: A Modifiable Driver of Inflammation, Frailty, and Aging. [PDF]

Curr HIV/AIDS Rep
Cabello Ubeda A, Erlandson KM, Freeman ML, Letendre SL, Wanjalla CN, Koethe JR, Corley MJ, Hunt PW, Gianella S.   +8 more
europepmc   +1 more source

Increasing the reporting of adverse drug reaction‐related hospitalizations using an ICD‐10‐based identification workflow: A multicentre study from Switzerland

British Journal of Clinical Pharmacology, EarlyView.
Background Reporting adverse drug reactions (ADRs) is essential for drug safety. In Switzerland, healthcare professionals are legally required to report serious and unlabelled ADRs, yet under‐reporting remains widespread. We tested a novel method to increase reporting of ADR‐related hospitalizations.
Georgia Anita Weber, Sophie‐Charlotte Bartel, Michael Boch, Christoph Rosen, Michael Bodmer, Balthasar Luzius Hug, Thomas Stammschulte, Patrick E. Beeler   +7 more
wiley   +1 more source

Intervention to Increase Uptake of Recommended Vaccines in an Inner-City HIV Care Clinic. [PDF]

AIDS Behav
Castro JG, Botero V, Rodriguez A.
europepmc   +1 more source

AIDS Vaccines at the Crossroads

, 2005
AIDS Vaccine Advocacy Coalition
core  

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe

British Journal of Clinical Pharmacology, EarlyView.
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis, Christine Leopold, Joyce M. Hoek, Raymond M. Schiffelers, Marie L. De Bruin   +4 more
wiley   +1 more source

Corrigendum to “Systematic identification of HEV ORF2 interactome reveals that TMEM134 engages in ORF2-mediated NF-κB pathway” [Virus Research 228 (2017) 102–108]

Virus Research
Yabin Tian, Weijin Huang, Jun Yang, Zhiheng Wen, Yansheng Geng, Chenyan Zhao, Heqiu Zhang, Youchun Wang   +7 more
doaj   +1 more source

Persistent immune dysfunction during suppressive antiretroviral therapy: implications for analytical treatment interruption trials for chronic HIV infections in sub-Saharan Africa. [PDF]

Front Immunol
Kankundiye P, Kia P, Kankaka E, Nabatanzi R, Mahmoudi T, Nakanjako D.   +5 more
europepmc   +1 more source